Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Star Diamond: High Modelled Diamond Prices and High Proportions of Type IIa Diamonds (click to learn more) Northstar Discovers Large Near Surface EM Conductor SE of Cam Copper Mine (click to learn more) Xcyte Digital Corp. Releases "Xperience" Subscription Service (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News LadRx Corp LADX

Healthcare Biotechnology
LadRx Corp is a biopharmaceutical research and development company specializing in oncology. The Company focuses on the discovery, research and clinical development of anti-cancer drug candidates that employ technologies that target chemotherapeutic drugs to solid tumors and reduce off-target toxicities. The Company’s linker activated drug release (LADR) technology platform consists of an... see more

Recent & Breaking News (OTCQB:LADX)

CytRx Announces Presentation of Interim Phase 2 Data for Aldoxorubicin for HIV-Related Kaposi's Sarcoma

PR Newswire June 29, 2015

Cheryl Cohen, Former Medivation Chief Commercial Officer, Joins CytRx Board of Directors

PR Newswire June 24, 2015

CytRx Announces Settlement of Stockholder Derivative Lawsuit in Delaware

PR Newswire June 2, 2015

CytRx to Present Aldoxorubicin Clinical Data at the 2015 ASCO Annual Meeting

PR Newswire May 27, 2015

CytRx to Present at the Jefferies 2015 Global Healthcare Conference

PR Newswire May 26, 2015

CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer)

PR Newswire May 21, 2015

CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers

PR Newswire May 4, 2015

CytRx Reports First Quarter 2015 Financial Results

PR Newswire May 1, 2015

CytRx Announces Publication of Glioblastoma Clinical Case Study in Journal of Nuclear Medicine & Radiation Therapy

PR Newswire April 29, 2015

GenSpera Looks Undervalued Compared to Its Peers

Accesswire April 27, 2015

Dr. Anita J. Chawla Joins CytRx Board of Directors to Add Additional Drug Commercialization Expertise in Oncology

PR Newswire March 11, 2015

CytRx Reports 2014 Financial Results

PR Newswire March 10, 2015

CytRx to Present at the Cowen & Company 35th Annual Health Care Conference

PR Newswire February 25, 2015

CytRx to Present at the 17th Annual BIO CEO & Investor Conference on February 9, 2015 in New York City

PR Newswire February 2, 2015

CytRx Announces Overall Survival Results from Its Global Phase 2b Clinical Trial of Aldoxorubicin in Soft Tissue Sarcoma

PR Newswire January 22, 2015

CytRx Announces FDA's Removal of Partial Clinical Hold for Aldoxorubicin Clinical Trials Permitting Immediate Enrollment of New Patients

PR Newswire January 20, 2015

CytRx Announces Positive Interim Phase 2 Aldoxorubicin Results as a Treatment for HIV-Related Kaposi's Sarcoma (KS)

PR Newswire January 8, 2015

CytRx Announces Positive Interim Phase 2 Aldoxorubicin Results in Glioblastoma Multiforme (Brain Cancer)

PR Newswire January 6, 2015

CytRx Receives Written FDA Communication Regarding Partial Clinical Hold for Aldoxorubicin Clinical Trials

PR Newswire December 3, 2014

CytRx to Present at the Oppenheimer 25th Annual Healthcare Conference

PR Newswire December 2, 2014